Compare MSM & CRNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MSM | CRNX |
|---|---|---|
| Founded | 1941 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.9B | 3.9B |
| IPO Year | 1996 | 2018 |
| Metric | MSM | CRNX |
|---|---|---|
| Price | $89.29 | $36.25 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 5 | 9 |
| Target Price | ★ $91.00 | $74.78 |
| AVG Volume (30 Days) | 530.7K | ★ 1.0M |
| Earning Date | 04-01-2026 | 05-07-2026 |
| Dividend Yield | ★ 3.79% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.93 | N/A |
| Revenue | ★ $3,363,817,000.00 | $1,039,000.00 |
| Revenue This Year | $5.88 | $722.66 |
| Revenue Next Year | $5.16 | $183.79 |
| P/E Ratio | $98.67 | ★ N/A |
| Revenue Growth | ★ 4.99 | N/A |
| 52 Week Low | $68.10 | $24.10 |
| 52 Week High | $96.99 | $57.99 |
| Indicator | MSM | CRNX |
|---|---|---|
| Relative Strength Index (RSI) | 48.54 | 37.03 |
| Support Level | $87.44 | $33.23 |
| Resistance Level | $89.68 | $37.23 |
| Average True Range (ATR) | 2.92 | 1.49 |
| MACD | -0.05 | 0.22 |
| Stochastic Oscillator | 50.34 | 53.29 |
Founded in 1941, MSC Industrial Direct originally manufactured and sold cutting tools to metalworking shops in New York. Through a series of acquisitions and organic expansions, MSC has grown into an industrial distribution powerhouse with a focus on specialized metalworking products and services. The firm also distributes a wide breadth of maintenance, repair, and operations supplies. MSC primarily operates in North America, where it derives over 95% of its revenue.
Crinetics Pharmaceuticals Inc is a commercial-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its main product, Palsonify (paltusotine), is a once-daily, oral treatment approved by the FDA for adults with acromegaly who have had an inadequate response to surgery and/or for whom surgery is not an option. Additionally, the company's development pipeline includes several programs, including a late-stage investigational candidate, atumelnant, currently in development for CAH and ADCS, and CRN09682, a NDC candidate that is being developed to treat SST2-expressing NETs and other SST2-expressing solid tumors.